Tesamorelin Is Approved. CJC-1295 Is Living Off Its Reputation.

The same message lands in my inbox three or four times a month, almost word for word: CJC/Ipamorelin is pretty well studied at this point, right? Sometimes there's a forum screenshot attached, and somewhere in the thread a confident guy has written the phrase "the GH peptide studies show."

That phrase is doing an enormous amount of unpaid labor.

Because "the GH peptide studies" isn't a body of evidence. It's a category name stretched over seven or eight compounds that have almost nothing in common evidentially. Tesamorelin is an approved GHRH analogue, approved for a specific clinical indication, used under medical supervision. CJC-1295, with DAC or without, is an unapproved one. Same mechanism family. Same paragraph in every listing description on the internet. Completely different paperwork.

What the new review actually set out to do

There's a newly indexed review pair on performance-enhancing peptides that modulate the GH, IGF-1 axis, and what makes it useful isn't a new finding. It's the organizing principle. The authors built the thing around the gap between what has been published clinically and what people are actually doing with these compounds outside clinical settings. They name CJC-1295, both with and without DAC, as among the unregulated peptides most commonly encountered in clinical practice and in online self-administration protocols.

Read that again. Clinicians are meeting this compound constantly. Not because it was prescribed.

And then the sentence that should reset how you read every product page in this category: the authors state that these peptides lack regulatory approval for physique- or performance-related indications, and that the underlying evidence ranges from regulatory-grade randomized trial data to a complete absence of human studies, leaving the putative performance and body-recomposition benefits uncertain.

Randomized trial data at one end. Zero human studies at the other. Same shelf. Same shopping cart.

The GH Evidence Ladder

So here's the lens I use, and I use it the same way every time. Four rungs.

Rung 1, Regulatory-grade human trials. Randomized human data supporting a specific clinical indication in a specific population. Tesamorelin is the recognizable name here. Two things about that: approval for a defined clinical indication under supervision is not a statement about buying a research vial, and the populations studied in that work are not healthy adults. You cannot slide those results sideways.